Table 2.

Summary of various parameters in different early conversion clinical trials

Table 2: Summary of various parameters in different early conversion clinical trials
Authors	Study design		Time of conversion	Group 1	Group 2
A) Everolimus
Budde, et al, 2011, (ZEUS Study) [23]	Multicenter randomized trial (n=300), 12 months, 36 months, 5 years	4.5th month		EVR (C0, 6–10 ng/mL) Induction: Basiliximab (n=155)	CsA ( C0, 120–180 ng/mL till 4.5–6 months then decreased to 100–150 ng/mL) Induction: Basiliximab (n=145)
Mjornstedt, et al, 2012, (CENTRAL trial) [24]	Multicenter randomized trial (n=269), 5 years	7th week		EVR (C0, 6–10 ng/mL) + MMF (1.4 g/d till 2 weeks then decreased to 1.08 g/d) + S (n=92)	Low CsA ( C0, 75–200 ng/mL till 2 weeks then decreased to 50–150 ng/mL) + MMF (1.4 g/d) + S (n=90)
B) Sirolimus
Lebranchu, et al, 2009, (CONCEPT Study) [25]	Multicenter randomized trial (n=193), 12 months, 48 months	3rd month		SRL (C0, 8–15 ng/mL till 39 weeks then decreased to 5–10 ng/ mL) + MMF + S Induction: Daclizumab (n=95)	CsA (C0, 500–800 ng/mL) + MMF + S Induction: Daclizumab (n=97)
Guba, et al, 2010, (SMART Trial) [26]	Multicenter randomized trial (n=140), 12 and 36 months	10–24th day		SRL (C0, 8–12 ng/mL then decreased to 5–10 ng/ mL) + MMF (1.5 g/d) + S Induction: ATG (n=69)	CsA (C0, 150–200 ng/mL then decreased to 100–150 ng/ mL) + MMF (2 g/d) + S Induction: ATG (n=71)
Weir, et al, 2010, (Spare the Nephron Trial) [27]	Multicenter randomized trial (n=299), 2 years	Within 115 days		MMF + SRL (n=148)	MMF + CNI (n=151)
Heilman, et al, 2011 [28]	Multicenter randomized trial (n=122), 24 months	1 month		SRL (C0, 9.8±3.6 ng/mL) + MMF + S Induction: Basiliximab (n=62)	TAC (C0, 6.9±4.6 ng/mL) + MMF + S Induction: Basiliximab (n=60)